Literature DB >> 14711304

Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.

Michael D Wendt1, Todd W Rockway, Andrew Geyer, William McClellan, Moshe Weitzberg, Xumiao Zhao, Robert Mantei, Vicki L Nienaber, Kent Stewart, Vered Klinghofer, Vincent L Giranda.   

Abstract

The preparation and assessment of biological activity of 6-substituted 2-naphthamidine inhibitors of the serine protease urokinase plasminogen activator (uPA, or urokinase) is described. 2-Naphthamidine was chosen as a starting point based on synthetic considerations and on modeling of substituent vectors. Phenyl amides at the 6-position were found to improve binding; replacement of the amide with other two-atom linkers proved ineffective. The phenyl group itself is situated near the S1' subsite; substitutions off of the phenyl group accessed S1' and other distant binding regions. Three new points of interaction were defined and explored through ring substitution. A solvent-exposed salt bridge with the Asp60A carboxylate was formed using a 4-alkylamino group, improving affinity to K(i) = 40 nM. Inhibitors also accessed two hydrophobic regions. One interaction is characterized by a tight hydrophobic fit made with a small dimple largely defined by His57 and His99; a weaker, less specific interaction involves alkyl groups reaching into the broad prime-side protein binding region near Val41 and the Cys42-Cys58 disulfide, displacing water molecules and leading to small gains in activity. Many inhibitors accessed two of these three regions. Affinities range as low as K(i) = 6 nM, and many compounds had K(i) < 100 nM, while moderate to excellent selectivity was gained versus four of five members of a panel of relevant serine proteases. Also, some selectivity against trypsin was generated via the interaction with Asp60A. X-ray structures of many of these compounds were used to inform our inhibitor design and to increase our understanding of key interactions. In combination with our exploration of 8-substitution patterns, we have identified a number of novel binding interactions for uPA inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14711304     DOI: 10.1021/jm0300072

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Hit clustering can improve virtual fragment screening: CDK2 and PARP1 case studies.

Authors:  Alexey A Zeifman; Victor S Stroylov; Fedor N Novikov; Oleg V Stroganov; Alexandra L Zakharenko; Svetlana N Khodyreva; Olga I Lavrik; Ghermes G Chilov
Journal:  J Mol Model       Date:  2011-11-09       Impact factor: 1.810

2.  2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.

Authors:  Archna P Massey; William R Harley; NagaRekha Pasupuleti; Fredric A Gorin; Michael H Nantz
Journal:  Bioorg Med Chem Lett       Date:  2012-01-04       Impact factor: 2.823

3.  Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.

Authors:  Mahmoud A Al-Sha'er; Mohammad A Khanfar; Mutasem O Taha
Journal:  J Mol Model       Date:  2014-01-28       Impact factor: 1.810

4.  Challenging the gold standard for 3D-QSAR: template CoMFA versus X-ray alignment.

Authors:  Bernd Wendt; Richard D Cramer
Journal:  J Comput Aided Mol Des       Date:  2014-06-17       Impact factor: 3.686

5.  6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.

Authors:  Benjamin J Buckley; Ashraf Aboelela; Elahe Minaei; Longguang X Jiang; Zhihong Xu; Umar Ali; Karen Fildes; Chen-Yi Cheung; Simon M Cook; Darren C Johnson; Daniel A Bachovchin; Gregory M Cook; Minoti Apte; Mingdong Huang; Marie Ranson; Michael J Kelso
Journal:  J Med Chem       Date:  2018-09-07       Impact factor: 7.446

6.  Lithium Hexamethyldisilazane Transformation of Transiently Protected 4-Aza/Benzimidazole Nitriles to Amidines and their Dimethyl Sulfoxide Mediated Imidazole Ring Formation.

Authors:  Reham A I Abou-Elkhair; Abdalla E A Hassan; David W Boykin; W David Wilson
Journal:  Org Lett       Date:  2016-09-08       Impact factor: 6.005

7.  Piperazine-2,3-dicarboxylic acid derivatives as dual antagonists of NMDA and GluK1-containing kainate receptors.

Authors:  Mark W Irvine; Blaise M Costa; Daniel Dlaboga; Georgia R Culley; Richard Hulse; Caroline L Scholefield; Palmi Atlason; Guangyu Fang; Richard Eaves; Richard Morley; Maria B Mayo-Martin; Mascia Amici; Zuner A Bortolotto; Lucy Donaldson; Graham L Collingridge; Elek Molnár; Daniel T Monaghan; David E Jane
Journal:  J Med Chem       Date:  2011-12-14       Impact factor: 7.446

8.  Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.

Authors:  Zhonghui Lin; Longguang Jiang; Cai Yuan; Jan K Jensen; Xu Zhang; Zhipu Luo; Barbara C Furie; Bruce Furie; Peter A Andreasen; Mingdong Huang
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

9.  Docking challenge: protein sampling and molecular docking performance.

Authors:  Khaled M Elokely; Robert J Doerksen
Journal:  J Chem Inf Model       Date:  2013-04-15       Impact factor: 4.956

10.  A potent and highly efficacious Bcl-2/Bcl-xL inhibitor.

Authors:  Angelo Aguilar; Haibin Zhou; Jianfang Chen; Liu Liu; Longchuan Bai; Donna McEachern; Chao-Yie Yang; Jennifer Meagher; Jeanne Stuckey; Shaomeng Wang
Journal:  J Med Chem       Date:  2013-03-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.